Albinterferon alfa-2b
Albinterferon alfa-2b is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
456 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | HP_0012115 | K75.9 | 20 | 45 | 62 | 34 | 52 | 196 |
| Hepatitis c | D006526 | — | B19.2 | 19 | 42 | 59 | 29 | 45 | 179 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 18 | 42 | 54 | 29 | 46 | 173 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 11 | 31 | 45 | 21 | 38 | 135 |
| Chronic hepatitis | D006521 | — | K73.9 | 10 | 17 | 20 | 10 | 8 | 59 |
| Hepatitis b | D006509 | — | — | 5 | 5 | 10 | 6 | 9 | 32 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 5 | 5 | 10 | 6 | 8 | 31 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 7 | 9 | 5 | 3 | 4 | 26 |
| Carcinoma | D002277 | — | C80.0 | 8 | 15 | 3 | 2 | 2 | 23 |
| Leukemia | D007938 | — | C95 | 4 | 13 | 4 | 1 | 1 | 21 |
Show 32 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 20 | 30 | 18 | — | 6 | 69 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 5 | 19 | 2 | — | — | 23 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 8 | 4 | — | — | 13 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 8 | 4 | — | — | 12 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | 8 | 2 | — | — | 11 |
| Recurrence | D012008 | — | — | 4 | 7 | 4 | — | — | 10 |
| Communicable diseases | D003141 | — | — | 3 | 4 | 3 | — | 1 | 9 |
| Polycythemia vera | D011087 | — | D45 | 1 | 3 | 6 | — | — | 9 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | 3 | 6 | — | — | 9 |
| Multiple myeloma | D009101 | — | C90.0 | — | 6 | 4 | — | — | 9 |
Show 38 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 3 | — | — | 1 | 6 |
| Sarcoma | D012509 | — | — | 2 | 2 | — | — | — | 4 |
| Colorectal neoplasms | D015179 | — | — | 2 | 3 | — | — | 1 | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 4 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 3 | — | — | — | 4 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | — | 3 | — | — | 1 | 4 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 1 | — | — | — | 3 |
| Neurofibroma | D009455 | EFO_0000622 | — | 1 | 2 | — | — | — | 3 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 3 | 2 | — | — | — | 3 |
| Glioma | D005910 | EFO_0000520 | — | — | 3 | — | — | — | 3 |
Show 48 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Breast carcinoma in situ | D000071960 | — | D05 | 1 | — | — | — | — | 1 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 2 | 2 |
| Intravenous substance abuse | D015819 | — | — | — | — | — | — | 1 | 1 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Cone dystrophy | D000077765 | — | — | — | — | — | — | 1 | 1 |
| Cone-rod dystrophies | D000071700 | — | — | — | — | — | — | 1 | 1 |
| Ataxia | D001259 | — | R27.0 | — | — | — | — | 1 | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
| Cerebellar ataxia | D002524 | HP_0001251 | — | — | — | — | — | 1 | 1 |
| Bilateral vestibulopathy | D000071699 | — | — | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Albinterferon alfa-2b |
| INN | albinterferon alfa-2b |
| Description | Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin. Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107842 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 4DVS4AG4DF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use